Quarterly report pursuant to Section 13 or 15(d)

Alternative Health Products

Alternative Health Products
6 Months Ended
Feb. 28, 2018
Alternative Health Products [Text Block]

Alternative Health Products


On November 12, 2014, the Company signed an agreement with Poppy’s Teas LLC (“PoViva”) and acquired 51% of ViPova™. On November 2, 2017, Lexaria announced that it acquired a 100% ownership interest in PoViva Tea, LLC, via cash compensation of $70,000, a waiver on certain debts owed to Lexaria, and a 5%, 20 - year royalty on net profits of ViPova Tea TM tea, coffee, and hot chocolate sales. No Lexaria stock or options were issued. The 20 -year royalty was determined to have a $Nil fair value as PoViva operates at a loss and future profitability is uncertain.


On August 11, 2015, Lexaria signed a license agreement with PoViva Tea LLC for $10,000, granting Lexaria a 35 -year non exclusive worldwide license to unencumbered use of PoViva Tea LLC’s IP Rights, including rights of resale. This license agreement ensures Lexaria has full access to the underlying patent pending infusion Technology (the “Technology”).

Issued Patent # Patent
Issuance Date
Patent Family
9474725 10/25/2016 Food and Beverage Compositions Infused With
US 9839612 B2 12/12/2017 Lipophilic Active Agents and Methods of Use Thereof

The patents are amortized over their legal life of 20 years.


      February 28     August 31  
      2018     2017  
      $     $  
  Balance – Beginning   62,827     53,997  
  Additions   32,042     9,699  
  Amortization   (528 )   (869 )
  Balance – Ending   94,341     62,827  

On December 12, 2017, Lexaria received patent US 9839612 B2 from the United States Patent and Trademark Office (“USPTO”) for the use of its technology as a delivery platform for all cannabinoids including THC; fat soluble vitamins; non steroidal anti-inflammatory pain medications (“NSAIDs”); and nicotine.